Cell and Gene Therapy for Autoimmune Disorders

18 Jan 2023
Modalities and Indications Track

3:30pm Chair Introduction

Samik Basu, Chief Scientific Officer, Cabaletta Bio


3:35pm Presentation: Taming Autoimmunity with CAR T

  • Introduction to Kyverna
  • CAR T Approach and differentiation
  • Getting to the clinic and the promise of CAR T for Autoimmunity

Karen Walker, Chief Technical Officer, Kyverna Therapeutics


3:50pm Presentation: Cell-Based Therapies for T cell Mediated Disease

  • the challenge of T cell targeting
  •  Building robust, modular cell-based therapies for T cell mediated autoimmune disease and T cell malignancies
  •  Combining machine learning and synthetic biology to optimize T cell modifying cell therapies

Cameron Gardner, Director of Research, Jura Bio


4:05pm Presentation: Developing CAR Tregs as Living Therapeutics for Type 1 Diabetes

  • Using CRISPR-Cas9 and homology-directed repair to modify human Tregs with precision
  • Assessing trafficking of engineered cells in humanized mouse models
  • Enhancing human Treg expansion with new modulators

Leonardo M.R. Ferreira, Assistant Professor of Microbiology and Immunology, Medical University of South Carolina


4:20pm Presentation: Engineered T cell Therapy for Autoimmune Disease

  • Cellular therapy has the potential to deliver durable complete responses for treatment refractory autoimmune disease.
  • Precision ablation of B cells may be sufficient to reset the immune system to a normal state.

Gwen Binder, President, Science & Technology, Cabaletta Bio


4:35pm Closing Panel with Q&A

With all session participants


Cameron Gardner
Director of Research
Gwen Binder
President, Science & Techology
Cabaletta Bio
Karen Walker
Chief Technical Officer
Kyverna Therapeutics
Leonardo M.R. Ferreira
Assistant Professor of Microbiology and Immunology
Medical University of South Carolina
Samik Basu
Chief Scientific Officer
Cabaletta Bio